
Using nanoparticles to deliver an experimental drug directly into triple-negative breast cancer cells could be an effective way to fight this very aggressive cancer, which has very few treatment options. The drug is a peptide that is unstable, and delivering it directly into cells means that it can reach its target before degrading.
So concludes a study led by Mohamed El-Tanani, a professor in the Institute for Cancer Therapeutics at the University of Bradford in the United Kingdom. He and his colleagues report their findings in the International Journal of Pharmaceutics.
The new drug – discovered by El-Tanani – is a protein fragment, or peptide, that blocks a cell-regulation protein called RAN, which promotes cancer cell division and proliferation.
Link para a notícia: Medical News Today







